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Abstract Mitochondrial dysfunction is well documented in
presymptomatic brain tissue with Parkinson’s disease (PD).
Identification of the autosomal recessive variant PARK6
caused by loss-of-function mutations in the mitochondrial
kinase PINK1 provides an opportunity to dissect pathogen-
esis. Although PARK6 shows clinical differences to PD, the
induction of alpha-synuclein “Lewy” pathology by PINK1-
deficiency proves that mitochondrial pathomechanisms are
relevant for old-age PD. Mitochondrial dysfunction is
induced by PINK1 deficiency even in peripheral tissues
unaffected by disease, consistent with the ubiquitous
expression of PINK1. It remains unclear whether this
dysfunction is due to PINK1-mediated phosphorylation of
proteins inside or outside mitochondria. Although PINK1
deficiency affects the mitochondrial fission/fusion balance,
cell stress is required in mammals to alter mitochondrial
dynamics and provoke apoptosis. Clearance of damaged
mitochondria depends on pathways including PINK1 and
Parkin and is critical for postmitotic neurons with high
energy demand and cumulative stress, providing a mecha-
nistic concept for the tissue specificity of disease.
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Parkinson’s Disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s Disease (AD),
manifesting usually at old age without a family history, just
like AD. The clinical course of PD starts with unspecific
symptoms such as hyposmia, constipation, depression and
sleep alterations that are attributed to degenerative changes
in the olfactory bulb, the gastrointestinal nervous system
and brainstem structures such as the dorsal motor vagal
nucleus and the locus coeruleus neurons. The locomotor
hallmark signs of PD develop later and present a deficiency
in spontaneous movement initiation, cogwheel rigidity,
impaired postural reflexes and rest tremor, caused mainly
by the degeneration of dopaminergic neurons projecting
from the midbrain substantia nigra to the striatum. The
resulting deficit in dopaminergic signaling can be counter-
acted efficiently with pharmacological therapy or deep
brain stimulation, postponing the immobility and depen-
dence of PD patients by more than 5 years until usually
cognitive deficits become limiting. A characteristic neuro-
pathological feature of PD is the presence of multi-protein
aggregates containing α-synuclein and ubiquitin in neuro-
nal cell bodies and processes, the so-called Lewy bodies
and Lewy neurites, which highlight the progression of the
disease through affected cell populations from the gut and
the olfactory bulb to the cerebral cortex (Braak et al. 2006).
The typical biochemical features of the affected brain tissue
include signs of respiratory complex I inhibition, signs of
oxidative stress as e.g. lipid peroxidation and DNA
damage, together with altered stress response pathways
such as the glutathione system.
Despite similarities in the diagnostic motor syndrome,
different forms of PD vary in the onset age as well as
progression severity and the presence of accessory signs.
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This is not only due to the different genetic background and
random life experiences of each patient but can be also
related to the specific factors that cause PD. These factors
include different neurotoxins inhibiting respiratory complex
I such as MPTP and pesticides (Winklhofer and Haass
2009), but also divalent ions like manganese (Gitler et al.
2009). In addition, mutations in different genes such as
α-synuclein (chromosomal gene locus PARK1/PARK4),
Parkin (PARK2), UCH-L1 (PARK5), PINK1 (PARK6), DJ-
1 (PARK7), LRRK2 (PARK8), ATP13A2 (PARK9), Omi1/
HtrA2 (PARK13), PLA2G6 (PARK14) and FBXO7
(PARK15) can result in PD (for a recent review see Gasser
2009).
Studying consanguineous PD families with early
manifestation around 30–40 years of age and particularly
mild progression, the autosomal recessive PD variant
PARK6 was demonstrated to be caused by loss-of-
function mutations in the protein PTEN induced putative
kinase 1 (PINK1) (Valente et al. 2004). PARK6 patients
also differ from idiopathic PD patients, since the therapeutic
benefit from dopamine substitution appears to last (Kessler
et al. 2005), and since olfactory, autonomic and cognitive
deficits, as well as postural tremor are rare, while drug-
induced dyskinesia is frequent. Therefore, a purely mito-
chondrial pathogenesis in such autosomal recessive patients
was claimed to contrast with protein aggregation pathome-
chanisms in sporadic idiopathic and autosomal dominant
forms of PD (Ahlskog 2009; Nishioka et al. 2009).
However, the recent documentation of a first PARK6 brain
autopsy confirmed the occurrence of Lewy pathology
(Samaranch et al. 2009, personal communication), transient
knock-down of PINK1 in neuroblastoma cells induced
aggregation of recombinant alpha-synuclein, and PARK6
patient fibroblasts as well as PINK1-KO mice showed
dysregulated expression of endogenous alpha-synuclein
(Hoepken et al. 2008; Gispert et al. 2009), supporting the
hypothesis that protein degradation/aggregation and synap-
tic pathology may occur in PARK6 just as in idiopathic PD.
Thus, the pathogenesis of different PD forms may converge
in common pathways of mitochondrial dysfunction, oxida-
tive stress and protein aggregation.
PINK1 loss-of-function induces mitochondrial
dysfunction
To understand the pathogenesis of PARK6, it is essential
to elucidate the consequences of PINK1 loss-of-function
mutations. PINK1 contains 581 amino acids including a
N-terminal mitochondrial targeting sequence and the
sequence of a serine-threonine kinase (Nakajima et al.
2003; Silvestri et al. 2005) (Fig. 1). The endogenous
physiological targets of PINK1 phosphorylation activity
are unknown, but two Parkinson’ disease proteins with
partial mitochondrial localization were claimed on the
basis of recombinant work, namely Parkin and Omi
(indirect via p38 phosphorylation), as well as the mito-
chondrial chaperone Trap1 (Plun-Favreau et al. 2007;
Pridgeon et al. 2007; Kim et al. 2008). PINK1 expression
was shown to be quite ubiquitous, to occur in brain
neurons rather than in glia (Blackinton et al. 2007) and to
correlate to mitochondrial mass (Scheele et al. 2007). The
cytoplasmic precursor of PINK1 is not immediately
cleaved and imported into mitochondria, but may remain
demonstrable together with the mature form visible as a
doublet band in western blotting, while some experiments
also suggested that mature PINK1 can be re-exported from
mitochondria to the cytoplasm (Beilina et al. 2005; Haque
et al. 2008;). A putative transmembrane domain was
reported together with evidence localizing PINK1 in the
mitochondrial outer membrane with the kinase domain
facing the cytoplasm (Zhou et al. 2008), while indepen-
dent studies provided evidence for PINK1 dimerization
and association with the respiratory chain complexes (Liu
Fig. 1 Putative 3D model of the PINK1 kinase domain. In view of the
homology of PINK1 sequences from the protein center onwards
except the C-terminus versus pak1 sequences representing the kinase
domains, the known x-ray structure of pak1 was used as template. The
3D model is tilted to show the putative regulatory loops (left, in pink),
the putative ATP channel (center, in yellow) and the loop containing
the pathogenic G309D missense mutation which led to the identifi-
cation of PINK1 as disease protein (center right). Missing from the
model are the N-terminal sequences which mediate mitochondrial
import (lower left), as well as the C-terminal sequences thought to
decide substrate specificity (upper right). The model was created
using Composer with the SYBYL 6.9 from Tripos (compare
Grudzinska et al. 2005)
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et al. 2009). Further, PINK1 was observed to regulate
calcium efflux via the mitochondrial Na(+)/Ca(2+) exchanger
(Gandhi et al. 2009) and was implicated in mitochondrial
trafficking via a multiprotein complex containing Miro,
Milton and Mitofilin (Weihofen et al. 2009).
To elucidate the downstream effects of PINK1 loss-of-
function and to model PARK6 pathogenesis, different
systems were employed such as D. melanogaster, C.
elegans, D. rerio and M. musculus mutants, patient skin
fibroblasts and recombinant cell lines with PINK1 knock-
down/knockout or with overexpression of a defective
kinase domain. The loss of functional PINK1 was found
to result in increased reactive oxygen species (ROS) levels,
enhanced lipid peroxidation, altered glutathione metabo-
lism, enhanced MnSOD levels, impaired glucose import, a
decrease of complex I respiration, ATP production, mito-
chondrial membrane potential and cristae length, a deficit in
mtDNA synthesis and levels, an overload of calcium,
uncontrolled cytochrome C release, elevated caspase-3
activity and GSK3beta activity (Wang et al. 2006, 2007;
Yang et al. 2006; Hoepken et al. 2007; Anichtchik et al.
2008; Gautier et al. 2008; Piccoli et al. 2008; Wood-
Kaczmar et al. 2008; Gandhi et al. 2009; Grünewald et al.
2009; Gegg et al. 2009; Gispert et al. 2009; Marongiu et al.
2009). Efficient rescue of this pathology was observed
with drugs such as the mitochondrial permeability
transition pore blocker cyclosporin A, the mitochondrial
calcium influx blocker ruthenium red and the GSK3beta
inhibitor LiCl (Anichtchik et al. 2008; Marongiu et al.
2009). The consequences of mitochondrial dysfunction for
the organism include defective axonal outgrowth observed
in PINK1 deficient C. elegans (Sämann et al. 2009). In
PINK1-KO mice, specific neuronal dysfunction such as
pathological neurotransmitter release, synaptic plasticity
and altered postsynaptic receptor sensitivity was docu-
mented in the dopaminergic nigrostriatal pathway (Kitada
et al. 2007; Martella et al. 2009), but neuronal cell death is
not demonstrable in PINK1 knockout mice (Kitada et al.
2007, 2009; Gispert et al. 2009; Martella et al. 2009).
These findings are compatible with established data that
identified enhanced ROS levels and lipid peroxidation as
events occurring before the degeneration of dopaminergic
nigrostriatal neurons in the brain of PD patients (Jenner et
al. 1992).
However, at present it remains unclear whether these
mitochondrial alterations are upstream consequences of
PINK1 loss-of-function, whether they are secondary to
altered mitochondrial distribution dynamics affecting the
physiological trafficking within neurons, or secondary to
altered mitochondrial repair/clearance in response to ran-
dom stimuli and stress events within neurons. Furthermore,
mitochondrial dysfunction appears to be present in neuronal
as well as peripheral cell types unaffected by PARK6, thus
providing no satisfactory understanding for the preferential
vulnerability of neurons, particularly of dopaminergic
neurotransmission.
PINK1 loss-of-function alters mitochondrial dynamics
The morphology of mitochondria is dynamic and can vary
from small, rounded, fragmented mitochondria via the more
usual tubular mitochondria to interconnected mitochondrial
networks (Bereiter-Hahn et al. 2008). The mitochondrial
morphology is altered by physiological changes such as
uncoupling (Lyamzaev et al. 2004), oxidative stress
(Pletjushkina et al. 2006; Jendrach et al. 2008), or apoptosis
(Perfettini et al. 2005).
In the D. melanogaster model, PINK1 knockout
results in mitochondrial fragmentation and swelling
(Deng et al. 2008; Poole et al. 2008; Yang et al. 2008),
correlating well with the extensive cell damage in this
fruit fly model. PINK1 was therefore interpreted to act
like the known mitochondrial fission factors Drp1, Fis1
and MTP18.
In mammalian cells, the role of PINK1 for mitochondrial
morphology remains controversial: In cortical neurons of
PINK1 knockout mice no changes (Gispert et al. 2009) or a
slight elongation of mitochondria (Gautier et al. 2008) were
reported, suggesting that a compensatory mechanism
maintains mitochondrial morphology quite stable in the
murine models. While some groups demonstrated PINK1 to
act also in human cells as a fission factor (Yang et al. 2008;
Jendrach, unpublished data), other researchers observed
increased mitochondrial fission shortly after a transient
knockdown of PINK1 (Exner et al. 2007; Dagda et al.
2009), and concluded that PINK1 acts like the known
fusion factors Mfn1, Mfn2 and Opa1. Three recent
publications link altered mitochondrial fission in PINK1
deficient cells to increased Drp1 activity (Sandebring et al.
2009; Lutz et al. 2009; Park et al. 2009). Thus, alterations
of mitochondrial fission/fusion balance are now hypothe-
sized to be part of the autophagic process degrading
dysfunctional mitochondrial fragments (Cherra et al. 2009,
Chu 2009), and to depend on the specific stressor
employed.
Role of PINK1 in stress response
The data presented above lead to the important question
why no murine model, not even a mouse with a triple
mutation (Parkin, DJ-1, PINK1) (Kitada et al. 2009),
exhibits altered mitochondrial morphology, neuronal Lewy
bodies or massive loss of dopamineric neurons, as are
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typical for PD. A possible explanation could be the short
life span of a mouse that lives only up to three years with
the respective mutation, while a human has to cope much
longer. In addition, laboratory mice live in a protected
environment, lacking exposure to various kinds of stressors
that humans encounter every day, and differ from humans
in key metabolic features as e.g. the capacity to synthesize
the antioxidant vitamin C.
This hypothesis is supported by a rising amount of
data implicating PINK1 in cellular stress response.
PINK1 expression is modulated by trophic stress such
as serum deprivation, ischemia and oxygen-glucose
deprivation, with PINK1 modulating intracellular
stress/trophism signals such as Akt phosphorylation
(Mei et al. 2009; Sakurai et al. 2009; Shan et al. 2009).
Although mitochondrial morphology was not altered in
the cortical neurons of PINK1 knockout mice and in
PARK6 patient fibroblasts cultured with high glucose
supplementation, altered mitochondrial morphology in
comparison to controls was observed under low glucose
culture for fibroblasts and after proteasomal stress in
mouse primary neurons (Exner et al. 2007; Gispert et al.
2009). The use of 4E-BP transfection or the drug
rapamycin to suppress protein synthesis, mimicking an
important neuronal reaction to stress, effectively amelio-
rates mitochondrial defects induced by PINK1 deficiency
(Tain et al. 2009).
The loss of functional PINK1 results in impaired
tolerance to mitochondrial stress, e.g. enhancing the
sensitivity of mitochondria to fragmentation upon exposure
to the complex I inhibitor rotenone (Sandebring et al. 2009)
and the vulnerability of dopaminergic neurons towards the
complex I inhibitor MPTP (Haque et al. 2008). Although
exposure to oxidative stress makes increased mitochondrial
damage and enhanced apoptosis rates apparent in PINK1-
deficient cells (Clark et al. 2006; Gautier et al. 2008; Haque
et al. 2008; Jendrach, unpublished data), murine models in
contrast to D. melanogaster show no discernible signs of
apoptosis in the unstressed state (Park et al. 2006; Clark et
al. 2006; Gautier et al. 2008; Gispert et al. 2009).
Conversely, overexpression of PINK1 in the neuronal cell
line PC12 protected cells against oxidative stress induced
apoptosis, an effect mediated by the direct phosphorylation
of TRAP1 (TNF receptor-associated protein 1) by PINK1
(Pridgeon et al. 2007). TRAP1 is a mitochondrial localized
chaperone that has been shown to reduce ROS directly in
mitochondria (Hua et al. 2007). Other chaperones such as
Cdc37/Hsp90 have also been shown to interact with PINK1
(Weihofen et al. 2008). This role of PINK1 during and after
oxidative stress could also explain the protective effects of
PINK1 overexpression observed in human neuroblastoma
lines (Petit et al. 2005) and with murine primary cortical
neurons (Haque et al. 2008).
Recent data indicate that the stress-protection role of
PINK1 may be mediated via Parkin and may involve repair
and clearance pathways. The ubiquitin E3 ligase parkin can
bind selectively to damaged mitochondria and participates
in the engulfment of damaged mitochondria in preautopha-
gosomal structures (Narendra et al. 2008). PINK1-mediated
phosphorylation of Parkin is a requirement for this
translocation, and the interaction of PINK1 and Parkin has
mutual effects on their solubility (Kim et al. 2008; Shiba et
al. 2009; Um et al. 2009; Xiong et al. 2009). Consequently
Parkin can rescue mitochondrial dysfunction after knockout
of PINK1 in D. melanogaster (Park et al. 2006; Yang et al.
2006) and also in HeLa cells (Exner et al. 2007). A loss of
parkin in D. melanogaster causes abnormal mitochondrial
morphologies and neuropathological dysfunction (Greene
et al. 2003; Whitworth et al. 2005). It has also been
reported that PINK1 acts through phosphorylation of Omi/
HtrA2 to preserve mitochondrial integrity (Plun-Favreau et
al. 2007). The role of PINK1 in mitochondrial clearance is
further supported by studies with primary cortical neurons
of PINK1 knock-out mice. Here, an inhibition of proteaso-
mal degradation led to strongly increased mitochondrial
aggregation (Gispert et al. 2009). These data agree with the
proposal of Narendra et al. (2008) that the PINK1/Parkin
pathway is involved in mitochondrial quality control and
affects mitochondrial clearance by autophagy. This is
especially important for postmitotic nerve cells because this
cell type is much more susceptible to cumulative oxidative
damage than proliferating cells such as fibroblasts, and this
concept might explain the selective vulnerability of dopami-
nergic nerve cells.
Taken together, the data presented here indicate that
PINK1 is important for mitochondrial maintenance
during and after stress. A loss of functional PINK1
results in an accumulation of damaged mitochondria,
rendering cells more susceptible to oxidative stress and
affecting neurotransmitter signaling. This explains why
the pathology of PARK6 appears only cumulatively with
age in postmitotic neurons. Further work is needed to
elucidate the interaction between PINK1 and other PD-
associated proteins in common molecular pathways, to
understand the mechanisms which ensure mitochondrial
quality control and distribution, and to analyze the
trophic stimuli and stress events which determine synap-
tic strength.
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